Table 2:

IPT initiation rate by trial group, overall and after excluding the 100-day IPT push occurring in Q3–2019, with subanalyses by sex and region

	IPT initiation per person-year (95% CI)		Incidence rate ratio (95% CI)	p value*
	Intervention	Control
Whole 2-year period
Overall	0·74 (0·59–0·88)	0·65 (0·55–0·75)	1·14 (0·88–1·46)	0·16
By sex
Men	0·78 (0·64–0·92)	0.69 (0·58–0·79)	1·13 (0·89–1·44)	0·15
Women	0·68 (0·54–0·80)	0·63 (0·52–0·73)	1·08 (0·83–1·41)	0·23
By region
Southwest	0·65 (0·41–0·90)	0·71 (0·50–0·92)	0·92 (0·57–1·48)	0·35
East-central	0·79 (0·62–0·95)	0·72 (0·58–0·86)	1·09 (0·81–1·46)	0·27
East	0·78 (0·42–1·15)	0·45 (0·23–0·67)	1·75 (0·89–3·44)	0·048
Excluding Q3-2019 (100-day IPT push)
Overall	0·32 (0·26–0·38)	0·25 (0·21–0·29)	1·27 (1·00–1·61)	0·026
By sex
Men	0·33 (0·28–0·38)	0·26 (0·22–0·30)	1·27 (1·03–1·56)	0·012
Women	0·30 (0·24–0·35)	0·25 (0·21–0·29)	1·21 (0·94–1·55)	0·068
By region
Southwest	0·31 (0·20–0·42)	0·29 (0·19–0·39)	1·07 (0·66–1·75)	0·38
East-central	0·32 (0·23–0·40)	0·25 (0·21–0·29)	1·25 (0·92–1·72)	0·073
East	0·34 (0·27–0·40)	0·20 (0·10–0·29)	1·71 (1·00–2·90)	0·024

IPT=isoniazid preventive therapy. Q3-2019=third quarter of 2019.

^*One-sided test of the null hypothesis that the trial intervention did not improve IPT initiation among adults in HIV care.